BioMarin announces new MPS IVA ERT clinical trial – 4 US sites

BioMarin has slots remaining in their MOR-008 clinical trial for patients with MPS IVA who are not participating in the phase III clinical trial.  There are four sites in the US: NYC, Chicago, Oakland and Houston.  This is a randomized, double-blind, pilot study of the safety and physiological effects of two doses of BMN 110 (enzyme replacement therapy) in patients age 7 or older who are able to walk a minimum of 200 meters.

If you are interested in this clinical trial or have questions about it, please contact Terence Eagleton, MD Senior Medical Director, BioMarin Europe Ltd., teagleton@bmrn.com, 415.506.3530.

This entry was posted in News and tagged . Bookmark the permalink.

Comments are closed.